3Z raises a $2M funding round for its preclinical research of new ADHD and Insomnia therapeutics
Recently, 3Z announced that it had closed a $2M funding round led by investors that have extensive experience in pharmaceuticals and medical technology. The new capital will be used to accelerate the finalization of preclinical studies on 3Z´s lead therapeutic candidates in ADHD and insomnia. Using its unique zebrafish